Maria P. Herrero Valent BioSciences Corporation 870 Technology Way Libertyville, IL 60048 Dear Ms. Herrero:

Subject: N, 6 Benzyladenine EPA Experimental Use Permit No. 73049 EUP 2 Effective Dates: to January 31, 2005 Quantity Authorized: 3924 lbs. active ingredient ( 1962 lbs. to be applied the first year, and 1962 lbs. to be applied the second year) Acres to be Treated: 9980 total acres [ 9680 acres of apples ( 4840 acres to be treated the first year, and 4840 acres to be treated the second year) and 300 acres of pistachios ( 150 acres to be treated each year)]

On the basis of the information furnished by the applicant and the annexed program, the subject Experimental Use Permit ( EUP) under section 5 of the Federal Insecticide, Fungicide, and Rodenticide Act is hereby issued for the above named plant regulator. The EUP, authorized only in the States of California, Idaho, Maine, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Utah, Vermont, Virginia, Washington, West Virginia and Wisconsin, will evaluate the experimental product's a) efficacy when used as an apple fruit thinner, b) efficacy in alleviating alternate bearing in pistachio, and c) effects when multiple low rates are applied for apple fruit sizing. Shipment and/ or use under this Permit is subject to the provisions of 40 CFR Part 172. 2 PRIOR TO SHIPMENT AND/ OR USE OF THIS MATERIAL, YOU MUST CONSULT WITH THE STATE PESTICIDE REGULATORY OFFICIALS OF THE STATES IN WHICH YOUR EXPERIMENTAL PROGRAM WILL BE CONDUCTED AND OBTAIN A STATE PERMIT OR LICENSE IF SUCH IS REQUIRED. YOU ARE REQUIRED TO PROVIDE NOTICE TO THE STATE PESTICIDE REGULATORY AGENCY AT LEAST 72 HOURS PRIOR TO THE APPLICATION OF THIS EXPERIMENTAL USE PRODUCT. YOU ARE TO NOTIFY THE STATE LEAD AGENCY OF THE STATES IN WHICH YOUR EXPERIMENTAL PROGRAM WILL BE CONDUCTED OF THE SPECIFIC TESTING PROGRAM ( WHEN, WHERE, HOW MUCH, ETC.). THE AGENCY IS ALSO NOTIFYING THE RELEVANT EPA REGIONS AND STATE REGULATORY OFFICIALS BY SENDING THEM COPIES OF THIS EXPERIMENTAL USE PERMIT. ISSUANCE OF THIS FEDERAL PERMIT DOES NOT NEGATE THE NEED FOR PERMISSION FROM THE INDIVIDUAL STATES. FAILURE TO DO SO MAY RESULT IN REVOCATION OR MODIFICATION OF THE EXPERIMENTAL USE PERMIT.

Based on the experimental program submitted, this product may be shipped for use under this permit to the following states.

State Acres, Per Year CA 310 ID 44 ME 200 MD 160 MA 300 MI 500 NJ 200 NY 600 NC 300 OH 200 OR 160 PA 500 UT 44 VT 200 VA 300 WA 600 WV 300 WI 72 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Total 4990 ( Per Year)

Grand Total 9980 ( Two Years) 3 A temporary exemption from the requirement of a tolerance for residues of the active ingredient, N, 6 benzyladenine, in or on the food commodities apples [ when applied at an application rate not to exceed 182 grams of active ingredient per acre per season ( g ai/ A/ season)] and pistachios [ when applied at an application rate not to exceed 60 g ai/ A/ season] has been established under provisions of the Federal Food, Drug and Cosmetic Act. This temporary tolerance exemption will expire on 1/ 31/ 2005.

All information required under regulations for registration will be required prior to registration or establishing permanent tolerances or exemptions from the requirement of a tolerance. Refer to 40 CFR Part 158.

Reporting to the Agency of any adverse reactions is required.

The label submitted in connection with the application for the EUP is acceptable, and a stamped copy is enclosed for your records. Submit five final printed labels, to which the permit number, 73049 EUP 2, preceded by " EPA Experimental Use Permit No." has been added. This label must be used for all shipments under this EUP and must be in the possession of the user at the time of application.

All cooperators must be provided a copy of this EUP authorization letter prior to the initial pesticide application made in accordance with this EUP.

The requirement for quarterly reports has been waived and the only report that you must provide is a final report at the conclusion of the experiment. The final report should include all of the items set forth in the 40 CFR 172.8( b).

Sincerely,

Janet L. Andersen, Ph. D. Director Biopesticides and Pollution Prevention Division ( 7511C)

Enclosure


[Federal Register Volume 88, Number 53 (Monday, March 20, 2023)]
[Notices]
[Pages 16642-16644]
[FR Doc No: 2023-05641]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-E-2805]

Determination of Regulatory Review Period for Purposes of Patent
Extension; IC-8 APTHERA INTRAOCULAR LENS

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) has
determined the regulatory review period for IC-8 APTHERA INTRAOCULAR
LENS and is publishing this notice of that determination as required by
law. FDA has made the determination because of the submission of an
application to the Director of the U.S. Patent and Trademark Office
(USPTO), Department of Commerce, for the extension of a patent which
claims that medical device.

DATES: Anyone with knowledge that any of the dates as published (see
SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic
or written comments and ask for a redetermination by May 19, 2023.
Furthermore, any interested person may petition FDA for a determination
regarding whether the applicant for extension acted with due diligence
during the regulatory review period by September 18, 2023. See
``Petitions'' in the SUPPLEMENTARY INFORMATION section for more
information.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of May 19, 2023. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are received on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and

identified, as confidential, if submitted as detailed in
``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2022-E-2805 for Determination of Regulatory Review Period for
Purposes of Patent Extension; IC-8 APTHERA INTRAOCULAR LENS. Received
comments, those filed in a timely manner (see ADDRESSES), will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with section 10.20 (21 CFR 10.20) and
other applicable disclosure law. For more information about FDA's
posting of comments to public dockets, see 80 FR 56469, September 18,
2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, Rm. 6250, Silver Spring, MD 20993,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    The Drug Price Competition and Patent Term Restoration Act of 1984
(Pub. L. 98-417) and the Generic Animal Drug and Patent Term
Restoration Act (Pub. L. 100-670) generally provide that a patent may
be extended for a period of up to 5 years so long as the patented item
(human drug product, animal drug product, medical device, food
additive, or color additive) was subject to regulatory review by FDA
before the item was marketed. Under these acts, a product's regulatory
review period forms the basis for determining the amount of extension
an applicant may receive.
    A regulatory review period consists of two periods of time: a
testing phase and an approval phase. For medical devices, the testing
phase begins with a clinical investigation of the device and runs until
the approval phase begins. The approval phase starts with the initial
submission of an application to market the device and continues until
permission to market the device is granted. Although only a portion of
a regulatory review period may count toward the actual amount of
extension that the Director of USPTO may award (half the testing phase
must be subtracted as well as any time that may have occurred before
the patent was issued), FDA's determination of the length of a
regulatory review period for a medical device will include all of the
testing phase and approval phase as specified in 35 U.S.C.
156(g)(3)(B).
    FDA has approved for marketing the medical device IC-8 APTHERA
INTRAOCULAR LENS. IC-8 APTHERA INTRAOCULAR LENS is indicated for
unilateral implantation for the visual correction of aphakia and to
create monovision in patients age 22 or older who have been diagnosed
with bilateral operable cataract, who have up to 1.5D of astigmatism in
the implanted eye and who do not have a history of retinal disease and
who are not predisposed to experiencing retinal disease in the future.
Subsequent to this approval, the USPTO received a patent term
restoration application for IC-8 APTHERA INTRAOCULAR LENS (U.S. Patent
No. 9,005,281) from AcuFocus, Inc., and the USPTO requested FDA's
assistance in determining this patent's eligibility for patent term
restoration. In a letter dated January 10, 2023, FDA advised the USPTO
that this medical device had undergone a regulatory review period and
that the approval of IC-8 APTHERA INTRAOCULAR LENS represented the
first permitted commercial marketing or use of the product. Thereafter,
the USPTO requested that FDA determine the product's regulatory review
period.

II. Determination of Regulatory Review Period

    FDA has determined that the applicable regulatory review period for
IC-8 APTHERA INTRAOCULAR LENS is 1,341 days. Of this time, 827 days
occurred during the testing phase of the regulatory review period,
while 514 days occurred during the approval phase. These periods of
time were derived from the following dates:
    1. The date an exemption under section 520(g) of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360j(g)) became effective:
November 21, 2018. FDA has verified the applicant's claim that the date
the investigational device exemption (IDE) for human tests to begin, as
required under section 520(g) of the FD&C Act, became effective
November 21, 2018.
    2. The date an application was initially submitted with respect to
the device under section 515 of the FD&C Act (21 U.S.C. 360e): February
24, 2021. FDA has verified the applicant's claim that the premarket
approval application (PMA) for IC-8 APTHERA INTRAOCULAR LENS (PMA
210005) was initially submitted February 24, 2021.
    3. The date the application was approved: July 22, 2022. FDA has
verified the applicant's claim that PMA 210005 was approved on July 22,
2022.
    This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the USPTO
applies several statutory limitations in its calculations of the actual
period for patent extension. In its application for patent extension,
this applicant seeks 928 days of patent term extension.

III. Petitions

    Anyone with knowledge that any of the dates as published are
incorrect may submit either electronic or written comments and, under
21 CFR 60.24, ask for a redetermination (see DATES). Furthermore, as
specified in section 60.30 (21 CFR 60.30), any interested person may
petition FDA for a determination regarding whether the applicant for
extension acted with due diligence during the regulatory review period.
To meet its burden, the petition must comply with all the requirements
of section 60.30, including but not limited to: must be timely (see
DATES), must be filed in accordance with section

10.20, must contain sufficient facts to merit an FDA investigation, and
must certify that a true and complete copy of the petition has been
served upon the patent applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format
specified in 21 CFR 10.30.
    Submit petitions electronically to https://www.regulations.gov at
Docket No. FDA-2013-S-0610. Submit written petitions (two copies are
required) to the Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

    Dated: March 14, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-05641 Filed 3-17-23; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: November 28, 2007 (Volume 72, Number 228)]
[Notices]
[Page 67296-67298]
[DOCID:fr28no07-45]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2007-0968; FRL-8339-9]

Chlormequat Chloride Reregistration Eligibility Decision for Low
Risk Pesticide; Notice of Availability

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces the availability of EPA's Reregistration
Eligibility Decision (RED) for the pesticide, chlormequat chloride, and
opens a public comment period on the RED, related risk assessments, and
other support documents. Chlormequat chloride is a plant growth
regulator registered for use on ornamental plants grown in greenhouses,
nurseries and shadehouses. Chlormequat chloride has no food or feed
uses, or U.S. tolerances associated with its use.
    EPA has reviewed the low risk pesticide, chlormequat chloride,
through a modified, streamlined version of the public participation
process that the Agency uses to involve the public in developing
pesticide reregistration and tolerance reassessment decisions. Through
these programs, EPA is ensuring that all pesticides meet current health
and safety standards.

DATES: Comments must be received on or before January 28, 2008.

ADDRESSES: Submit your comments, identified by docket identification
(ID) number EPA-HQ-OPP-2007-0968, by one of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the on-line instructions for submitting comments.
     Mail: Office of Pesticide Programs (OPP) Regulatory Public
Docket (7502P),

Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460-0001.
     Delivery: OPP Regulatory Public Docket (7502P),
Environmental Protection Agency, Rm. S-4400, One Potomac Yard (South
Bldg.), 2777 S. Crystal Dr., Arlington, VA. Deliveries are only
accepted during the Docket's normal hours of operation (8:30 a.m. to 4
p.m., Monday through Friday, excluding legal holidays). Special
arrangements should be made for deliveries of boxed information. The
Docket Facility telephone number is<PHONE_NUMBER>.
    Instructions: Direct your comments to docket ID number EPA-HQ-OPP-
2007-0968. EPA's policy is that all comments received will be included
in the docket without change and may be made available on-line at
http://www.regulations.gov, including any personal information
provided, unless the comment includes information claimed to be
Confidential Business Information (CBI) or other information whose
disclosure is restricted by statute. Do not submit information that you
consider to be CBI or otherwise protected through regulations.gov or e-
mail. The regulations.gov website is an ``anonymous access'' system,
which means EPA will not know your identity or contact information
unless you provide it in the body of your comment. If you send an e-
mail comment directly to EPA without going through regulations.gov,
your e-mail address will be automatically captured and included as part
of the comment that is placed in the docket and made available on the
Internet. If you submit an electronic comment, EPA recommends that you
include your name and other contact information in the body of your
comment and with any disk or CD-ROM you submit. If EPA cannot read your
comment due to technical difficulties and cannot contact you for
clarification, EPA may not be able to consider your comment. Electronic
files should avoid the use of special characters, any form of
encryption, and be free of any defects or viruses.
    Docket: All documents in the docket are listed in the docket index
available in regulations.gov. To access the electronic docket, go to
http://www.regulations.gov, select ``Advanced Search,'' then ``Docket
Search.'' Insert the docket ID number where indicated and select the
``Submit'' button. Follow the instructions on the regulations.gov
website to view the docket index or access available documents.
Although listed in the index, some information is not publicly
available, e.g., CBI or other information whose disclosure is
restricted by statute. Certain other material, such as copyrighted
material, is not placed on the Internet and will be publicly available
only in hard copy form. Publicly available docket materials are
available either in the electronic docket at http://
www.regulations.gov, or, if only available in hard copy, at the OPP
Regulatory Public Docket in Rm. S-4400, One Potomac Yard (South Bldg.),
2777 S. Crystal Dr., Arlington, VA. The hours of operation of this
Docket Facility are from 8:30 a.m. to 4 p.m., Monday through Friday,
excluding legal holidays. The Docket Facility telephone number is (703)
305-5805.

FOR FURTHER INFORMATION CONTACT: Joy Schnackenbeck, Special Review and
Reregistration Division (7508P), Office of Pesticide Programs,
Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>; fax
number:<PHONE_NUMBER>; e-mail address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

    This action is directed to the public in general, and may be of
interest to a wide range of stakeholders including environmental, human
health, and agricultural advocates; the chemical industry; pesticide
users; and members of the public interested in the sale, distribution,
or use of pesticides. Since others also may be interested, the Agency
has not attempted to describe all the specific entities that may be
affected by this action. If you have any questions regarding the
applicability of this action to a particular entity, consult the person
listed under FOR FURTHER INFORMATION CONTACT.

B. What Should I Consider as I Prepare My Comments for EPA?

    1. Submitting CBI. Do not submit this information to EPA through
regulations.gov or e-mail. Clearly mark the part or all of the
information that you claim to be CBI. For CBI information in a disk or
CD-ROM that you mail to EPA, mark the outside of the disk or CD-ROM as
CBI and then identify electronically within the disk or CD-ROM the
specific information that is claimed as CBI. In addition to one
complete version of the comment that includes information claimed as
CBI, a copy of the comment that does not contain the information
claimed as CBI must be submitted for inclusion in the public docket.
Information so marked will not be disclosed except in accordance with
procedures set forth in 40 CFR part 2.
    2. Tips for preparing your comments. When submitting comments,
remember to:
    i. Identify the document by docket ID number and other identifying
information (subject heading, Federal Register date and page number).
     ii. Follow directions. The Agency may ask you to respond to
specific questions or organize comments by referencing a Code of
Federal Regulations (CFR) part or section number.
    iii. Explain why you agree or disagree; suggest alternatives and
substitute language for your requested changes.
    iv. Describe any assumptions and provide any technical information
and/or data that you used.
    v. If you estimate potential costs or burdens, explain how you
arrived at your estimate in sufficient detail to allow for it to be
reproduced.
    vi. Provide specific examples to illustrate your concerns and
suggest alternatives.
    vii. Explain your views as clearly as possible, avoiding the use of
profanity or personal threats.
    viii. Make sure to submit your comments by the comment period
deadline identified.

II. Background

A. What Action is the Agency Taking?

    Under section 4 of the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA), EPA is reevaluating existing pesticides to
ensure that they meet current scientific and regulatory standards.
Using a modified, streamlined version of its public participation
process, EPA has completed a RED for the pesticide, chlormequat
chloride under section 4(g)(2)(A) of FIFRA. Chlormequat chloride is a
plant growth regulator registered for use on ornamental plants grown in
greenhouses, nurseries and shadehouses. Chlormequat chloride has no
food or feed uses, or U.S. tolerances associated with its use. EPA has
determined that the data base to support reregistration is
substantially complete and that products containing chlormequat
chloride are eligible for reregistration provided the risks are
mitigated either in the manner described in the RED or by another means
that achieves equivalent risk reduction. Upon submission of any
required product-specific data under section 4(g)(2)(B) of FIFRA and
any necessary changes to the registration and labeling (either to
address concerns identified in the RED or as a result of product-
specific data), EPA will make a

final reregistration decision under section 4(g)(2)(C) of FIFRA for
products containing chlormequat chloride.
    EPA is applying the principles of public participation to all
pesticides undergoing reregistration and tolerance reassessment. The
Agency's Pesticide Tolerance Reassessment and Reregistration; Public
Participation Process, published in the Federal Register on May 14,
2004, (69 FR 26819) (FRL-7357-9) explains that in conducting these
programs, EPA is tailoring its public participation process to be
commensurate with the level of risk, extent of use, complexity of
issues, and degree of public concern associated with each pesticide.
Due to its uses, risks, and other factors, chlormequat chloride was
reviewed through a modified process. Once EPA assesses uses and risks
for such low risk pesticides, the Agency may go directly to a decision
and prepare a document summarizing its findings such as the chlormequat
chloride RED.
    The reregistration program is being conducted under congressionally
mandated time frames, and EPA recognizes the need both to make timely
decisions and to involve the public. The Agency is issuing the
chlormequat chloride RED for public comment. This comment period is
intended to provide an opportunity for public input and a mechanism for
initiating any necessary amendments to the RED. All comments should be
submitted using the methods in ADDRESSES, and must be received by EPA
on or before the closing date. These comments will become part of the
Agency Docket for chlormequat chloride. Comments received after the
close of the comment period will be marked ``late.'' EPA is not
required to consider these late comments.
    The Agency will carefully consider all comments received by the
closing date and will provide a Response to Comments Memorandum in the
Docket and regulations.gov. If any comment significantly affects the
document, EPA also will publish an amendment to the RED in the Federal
Register. In the absence of substantive comments requiring changes, the
chlormequat chloride RED will be implemented as it is now presented.

B. What is the Agency's Authority for Taking this Action?

    Section 4(g)(2) of FIFRA, as amended, directs that, after
submission of all data concerning a pesticide active ingredient, the
Administrator shall determine whether pesticides containing such active
ingredient are eligible for reregistration, before calling in product-
specific data on individual end-use products and either reregistering
products or taking other ``appropriate regulatory action.''

List of Subjects

    Environmental protection, Pesticides and pests.

    Dated: November 17, 2007.
Steven Bradbury,
Director, Special Review and Reregistration Division, Office of
Pesticide Programs.
[FR Doc. E7-23053 Filed 11-27-07; 8:45 am]

BILLING CODE 6560-50-S


Industrial Economics, Inc (IEc) Documents Referenced in Preamble or used as Supporting Documents for RIA

   1.    Methodology for Secondary Containment for Piping (Work Assignment 1-19, Task 5), October 3, 2008

   2.    Small Entities Screening Analysis of UST Universe by Industry Sector (Work Assignment 3-25, Task 4), February 4, 2010

   3.    Detailed Assessment of UST Universe by Tank Purpose and Design (Work Assignment 1-25, Task 6), March 24, 2009        4.    Preliminary Assessment and Scoping of Data Related to Potential Revisions to the UST Regulations (Work Assignment 1-25, Tasks 2-4), November 20, 2008        5.    Draft Methodology for Assessing Cost-Effectiveness of Operator Training Options (Work Assignment 1-19, Task 4), December 30, 2008        6.    Detailed Assessment of UST Universe by Tank Use and Industry Sector (Work Assignment 1-25, Task 6), January 23, 2009


[Federal Register: July 17, 2009 (Volume 74, Number 136)]
[Proposed Rules]
[Page 34707]
[DOCID:fr17jy09-11]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Pipeline and Hazardous Materials Safety Administration

49 CFR Part 192

[Docket No. PHMSA-2009-0203]

Pipeline Safety: Notice of Technical Pipeline Safety Advisory
Committee Meetings

AGENCY: Pipeline and Hazardous Materials Safety Administration (PHMSA);
DOT.

ACTION: Notice of technical pipeline safety advisory committee
meetings.

-----------------------------------------------------------------------

SUMMARY: This notice announces a public meeting of the Technical
Pipeline Safety Standards Committee (TPSSC) and of the Technical
Hazardous Liquid Pipeline Safety Standards Committee (THLPSSC).
    The PHMSA staff will brief the committee members on pipeline
regulatory actions and policy concerns. The purpose of the meeting is
to keep the members updated on current safety concerns, proposed rules,
and future proposals.

DATES: The meeting will be on Thursday, August 6, 2009, from 1 p.m. to
5 p.m. EST. The TPSSC and the THLPSSC will take part in the meeting by
telephone conference call. The public may attend the meeting at the
U.S. Department of Transportation, 1200 New Jersey Avenue, SE.,
Washington, DC 20590, Room E27-302. Please contact the individual
listed under ``FOR FURTHER INFORMATION CONTACT'' by July 27, 2009.

FOR FURTHER INFORMATION CONTACT: For information about the meetings,
contact Cheryl Whetsel by phone at<PHONE_NUMBER> or by e-mail at
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Meeting Details

    Members of the public may attend and make a statement during the
advisory committee meetings. For a better chance to speak at the
meetings, please contact the individual listed under ``FOR FURTHER
INFORMATION CONTACT'' by July 27, 2009.

Privacy Act Statement

    Anyone may search the electronic form of comments received in
response to any of our dockets by the name of the individual submitting
the comment (or signing the comment, if submitted on behalf of an
association, business, labor union, etc.). DOT's complete Privacy Act
Statement was published in the Federal Register on April 11, 2000 (65
FR 19477).

Information on Services for Individuals With Disabilities

    For information on facilities or services for individuals with
disabilities, or to seek special assistance at the meetings, please
contact Cheryl Whetsel at<PHONE_NUMBER> by July 27, 2009.

II. Committee Background

    These two statutorily-mandated committees advise PHMSA on proposed
safety standards, risks assessments, and safety policies for natural
gas pipelines and for hazardous liquid pipelines. Both committees fall
under the Federal Advisory Committee Act (Pub. L. 92-463, 5 U.S.C. App.
1) and both are mandated by the pipeline safety law (49 U.S.C. Chap.
601). Each committee consists of 15 members--with membership evenly
divided among the Federal and State government, the regulated industry,
and the public. The committees advise PHMSA on technical feasibility,
practicability, and cost-effectiveness of each proposed pipeline safety
standard.

III. Preliminary Agenda

    The PHMSA will discuss its pipeline safety regulatory program, and
the following proposed rules or topics of interest. The committee will
not be voting on any proposals at this meeting.
    1. One-Rule and Changes to Incident and Accident Forms.
    2. Periodic Updates of Regulatory References to Technical
Standards.
    3. Low Stress II--Survey Results.
    4. Installing Excess Flow Valves (EFV)--(Application for Apartments
and Commercial Properties)
    5. Community Technical Assistance Grant Program.
    6. Pipelines and Informed Planning Alliance (PIPA).

    Issued in Washington, DC, on July 9, 2009.
Jeffrey D. Wiese,
Associate Administrator for Pipeline Safety.
[FR Doc. E9-16965 Filed 7-16-09; 8:45 am]

BILLING CODE 4910-60-P